Loading organizations...
RICOVR Healthcare develops the XALIVA® rapid diagnostics platform, offering non-invasive, high-accuracy, point-of-care testing primarily for recent cannabis (THC) use. Their core product, XALIVA® THC, utilizes an optical biosensor within a portable device and disposable cartridges, enabling quick and cost-effective on-site screening. The technology focuses on detecting all forms of ingested THC through saliva collection, maintaining privacy and providing rapid results in minutes.
The company was co-founded by Dr. Himanshu Bhatia, who serves as CEO, and Piyush Sadana, a Columbia Business School alumnus. Dr. Bhatia, a physician-scientist with extensive experience in medical devices, identified a critical need for accessible and accurate point-of-care diagnostics. This insight led to the creation of a solution that provides timely and reliable information for immediate decision-making.
RICOVR's product serves employers and Third-Party Administrators across various sectors such as construction, manufacturing, and logistics. These clients utilize XALIVA® for scenarios including random testing, post-accident checks, and return-to-duty screenings, aiming to enhance workplace safety, productivity, and regulatory compliance. The company envisions empowering organizations with efficient, on-site diagnostic tools to foster secure and productive environments.
RICOVR Healthcare has raised $1.0M across 1 funding round.
RICOVR Healthcare has raised $1.0M in total across 1 funding round.
RICOVR Healthcare is a Princeton, New Jersey-based technology company founded in 2018 that develops the XALIVA rapid diagnostics platform, enabling high-quality, point-of-care testing using small saliva samples.[1][2][4] The platform targets rapid tests for Covid-19, THC (cannabis), drugs-of-abuse, and infectious diseases, serving workplaces, employers, and healthcare providers to enhance safety and diagnostics.[1][3][6] It addresses the need for fast, accurate, non-invasive screening—particularly for recent THC use in high-risk industries—amid rising cannabis legalization, with products like XALIVA THC gaining traction for on-site detection to curb impairment-related risks.[3][6] The company has secured NIH grants, raised under $5M across three funding rounds, and maintains revenue below $5M with fewer than 25 employees, showing steady growth in point-of-care innovation.[1]
RICOVR Healthcare emerged in 2018 in Princeton, New Jersey, driven by a team of scientists, engineers, and entrepreneurs focused on saliva-based diagnostics to impact society positively.[1][4] Key figures include leaders with 20+ years in medical device R&D, commercialization (over 50 health-tech products), investment banking, RNA biochemistry, and B2B sales with Fortune 500 firms; notable team members hold degrees from Rutgers and UT Austin.[4] The advisory board features heavyweights like a former Quest Diagnostics President & CEO with 35+ years in healthcare leadership, plus experts in diversity solutions and public health boards.[1][4] Early momentum built through partnerships with global research institutions and manufacturers, culminating in NIH grants—like one in July 2024 for advancing XALIVA cannabis screening—and a pipeline expansion amid Covid-19 testing demands.[1]
RICOVR rides the point-of-care diagnostics wave, fueled by post-pandemic decentralization of testing, cannabis legalization (expanding workplace screening needs), and demand for rapid, user-friendly tools over lab-dependent methods.[1][3][6] Timing aligns with regulatory shifts and NIH support for innovative screening, positioning XALIVA amid a market projected to grow with telehealth and occupational health integration.[1] It influences the ecosystem by partnering with research institutions, advancing saliva tech for broader applications, and enabling employers—especially in safety-critical fields—to mitigate risks from rising THC use, thus bridging healthcare tech with HR and compliance.[3][4][6]
RICOVR is poised to scale XALIVA THC and pipeline expansions via NIH momentum and partnerships, targeting explosive growth in cannabis testing as legalization spreads.[1][6] Trends like AI-enhanced diagnostics, workplace wellness mandates, and global infectious disease vigilance will propel it, potentially evolving from niche player to diagnostics staple through B2B adoption in high-risk industries.[3][4] As saliva tech matures, RICOVR could redefine rapid screening, amplifying its societal impact from Princeton's labs to everyday safety protocols—echoing its founding commitment to innovative, accessible healthcare.[1][2]
RICOVR Healthcare has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in April 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2020 | $1M Seed | — | Halley Venture Partners | Announced |
RICOVR Healthcare has raised $1.0M in total across 1 funding round.
RICOVR Healthcare's investors include HALLEY Venture Partners.
